Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

NCT07070323 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT07070323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07070323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Lead sponsor
Beijing GoBroad Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 9, 2025
Completion date
December 31, 2026
Enrollment
54 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, refractory acute lymphoblastic leukemia, t-cell acute lymphocytic leukemia, t-cell malignancies